Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU (COVIDOP-DVT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04363528 |
Recruitment Status :
Active, not recruiting
First Posted : April 27, 2020
Last Update Posted : August 5, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The main objective of the study is to determine the incidence of deep vein thromboses at Doppler echo in patients with SARS-Cov-2 pneumopathy upon their entry into ICU and after 7 days of hospitalization in ICU.
This is a monocentric interventional study (RIPH 2).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Deep Vein Thrombosis | Other: Doppler Echo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU |
Actual Study Start Date : | April 24, 2020 |
Actual Primary Completion Date : | December 30, 2020 |
Estimated Study Completion Date : | December 30, 2021 |

Arm | Intervention/treatment |
---|---|
Doppler Echo
patients will have a Doppler Echo when they enter ICU (within 48 hours) and a second Doppler Echo 7 days later
|
Other: Doppler Echo
2 doppler echo will be done at patients hospitalized in ICU and with SARS-CoV-2 pneumopathy at 7 days apart |
- Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU [ Time Frame: Day 0 ]Deep vein thrombosis at Doppler echo
- Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU [ Time Frame: Day 7 ]Deep vein thrombosis at Doppler echo

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient > or =18 years
- Hospitalization in intensive care
- PCR COVID 19+ or compatible clinical signs (fever, cough, myalgia, asthenia, loss of taste, anosmia) associated with compatible radiological signs
Exclusion Criteria:
- Pregnancy in progress
- Patient <18 years
- Patients deprived of freedoms or under guardianship
- Patient or family opponent of protocol participation
- patient on curative anticoagulant for more than 48H00
- impossible Venous Doppler Echo

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04363528
France | |
Centre Hospitalier de Versailles | |
Le Chesnay, France, 78150 |
Responsible Party: | Aurelien Maurizot, coordonator investigator, Versailles Hospital |
ClinicalTrials.gov Identifier: | NCT04363528 |
Other Study ID Numbers: |
P20/08_COVIDOP-DVT |
First Posted: | April 27, 2020 Key Record Dates |
Last Update Posted: | August 5, 2021 |
Last Verified: | August 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Deep Vein Thrombosis doppler echo SARS-CoV-2 ICU |
Thrombosis Venous Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases |